Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the ...

The Company’s nsPFA™ System demonstrates the ability to provide cardiac ablation and mapping capabilities with a single catheter in preclinical studies The Company collaborated with CardioNXT to ...

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission “Since joining the Company’s Board last year I have ...

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in ...

Successfully treated atrial fibrillation (AF) in initial 30 patients with the Nanosecond PFA 360° Cardiac Catheter “The remap results for the first 30 patients treated with the Nanosecond PFA 360° ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug Administration (FDA) clearance of ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) ...

Management reiterated expectations to generate initial revenue from the percutaneous electrode in the second half of the year, noting, “This initial revenue recognition will value based on the ...

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting Pulse Biosciences ...

Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, ...